
By: Mark L. Sirower & Jeff M. Weirens (Harvard Business Review)
One of the critical mistakes that acquirers make is the mismanagement of Announcement Day, which usually arrives in the form of a carefully staged conference call packed with journalists and analysts — and plenty of excitement. Then investors react to the acquirer’s presentation. For the majority of companies, those reactions come as a harsh surprise, with the acquirer’s stock dropping — investors feel the pain immediately.
To put it bluntly, you simply can’t mess up Announcement Day. If you stumble in clearly and effectively conveying the logic and economics of the deal on Announcement Day, you will give investors reasons to sell — and the value lost from the stock-price drop is likely to only get worse. If the presentation goes awry, what investors hear is that management doesn’t have a plan and they react accordingly.
What The Data Says
For our book The Synergy Solution, we studied 1,267 deals across three major M&A waves between 1995–2018 and looked at how investors reacted to each deal around Announcement Day, and how those deals performed over the year following the deal relative to their industry peers. Together, the deals constitute more than $5 trillion of equity value with over $1 trillion of acquisition premiums. The average market capitalization of sellers relative to their acquirer was 46% — very significant deals for acquirers…
Featured News
Meta Begins Defense After FTC Concludes Case in Landmark Antitrust Trial
May 15, 2025 by
CPI
UK Data Bill Still No Closer to Passage As Parliamentary ‘Ping-Pong’ Drags On
May 15, 2025 by
CPI
Regeneron Pharmaceuticals Awarded $271.2M in Damages Against Amgen
May 15, 2025 by
CPI
FTC Chair Proposes 15% Staff Reduction Amid Budget Constraints
May 15, 2025 by
CPI
UK Urges Antitrust Watchdog to Prioritize Growth and Clarity in Business Regulation
May 15, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas